Clinical study of abiraterone acetate combined with androgen deprivation therapy in the treatment of high-risk metastatic hormone sensitive prostate cancer
Objective To investigate the efficacy and safety of abiraterone acetate combined with androgen deprivation therapy (ADT) in the treatment of high-risk metastatic sensitive prostate cancer (mHSPC).Methods 30 newly diagnosed high-risk mHSCP patients were included and randomly divided into observation group and control group,with 15 cases in each group.The observation group were treated with abiraterone acetate combined with prednisone and goserelin acetate,while the control group were treated with bicalutamide combined with goserelin acetate.And then,serum prostate-specific antigen ( PSA) levels,testosterone levels,alkaline phosphatase ( ALP ) levels,PSA progression and the occurrence of adverse reactions after treatment were compared between the two groups.Results (1) The PSA and testosterone levels of the observation group were lower than those of the control group at 3,6,9,and 12 months after treatment (P<0.05).(2) There was a positive correlation between serum ALP and PSA levels in the two groups after 6 months of treatment (P=0.046),while there was no statistical correlation at other time points ( P>0.05).After 12 months of treatment,both the ob-servation group and the control group could be observed a decrease in serum ALP levels,but difference was not statistically significant between groups (P>0.05).(3) Within 12 months of follow-up,no significant progression of PSA was observed in the observation group,while 5 patients in the control group showed PSA progression and met the diagnostic criteria of me-tastatic castration-resistant prostate cancer (mCRPC),and difference was statistically significant (P<0.05).(4) Within 12 months of follow-up,adverse reactions occurred in 3 and 2 patients in the observation group and the control group,respec-tively,and no patients suspended or changed treatment regimen due to adverse reactions,and the difference was not statisti-cally significant (P>0.05).Conclusion Compared with traditional bicalutamide combined with ADT regimen,abiraterone acetate combined with ADT in the treatment of high-risk mHSPC can reduce PSA and testosterone levels more quickly and deeply,delay the time of progression to mCRPC,and do not significantly increase the adverse reactions of patients.
metastatic hormone-sensitive prostate cancer(mHSPC)abiraterone acetatebicalutamideprospective study
万方数据
维普
